Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance a Phase II Clinical Study
Latest Information Update: 22 Jan 2025
At a glance
- Drugs JSKN 016 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Alphamab Biopharmaceuticals
- 22 Jan 2025 New trial record